参考文献/References:
[1] Tan GM,Wu E,Lam YY,et al.Role of warfarin pha-rmacogenetic testing in clinical practice[J].Pharmacogenomics,2010,11(3):439-448.
[2] Mahajan P,Meyer KS,Wall GC,et al.Clinical applications of pharmacogenomics guided warfarin dosing[J].Int J Clin Pharm,2013,35(3):359-368.
[3] Johnson JA,Gong L,Whirl-Carrillo M,et al.Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarindosing[J].Clin Pharmacol Ther,2011,90(4):625-629.
[4] Food and Drug Administration.Coumadin Labeling.Updated January 22,2010.Available at:FDA.Accessed October 2,2011.
[5] WarfarinDosing.org.Accessed October 2,2011.
[6] Gong IY,Tirona RG,Schwarz UI,et al.Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiationof therapy[J].Blood,2011,118(11):3163-3171.
[7] Burmester JK,Berg RL,Yale SH,et al.A randomized controlled trial of genotype-based coumadin initiation[J].Genet Med,2011,13(6):509-518.
[8] 张亚楠,崔 炜,韩 梅,等.河北省汉族人群CYP 450 2C9 和VKORC1基因多态性与华法林剂量相关性研究[J].中华流行病学杂志,2010,31(2):218-222.
Zhang YN,Cui W,Han M,et al.Gene polymorphism of CYP450 2C9 and VKORCl in Chinese population and their relationships to the maintaining dosage ofwarfarin[J]. Chin J Epidemiol,2010,31(2):218-222.
[9] Loebstein R,Yonath H,Peleg D,et al.Interindividual variability in sensitivity to warfarin-nature or nurture?[J].Clin Pharmacol Ther,2001,70(2):159-164.
[10] Hillman MA,Wilke RA,Caldwell MD,et al.Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype[J].Pharmacogenetics,2004,14(8):539-547.
[11] Kamali F,Khan TI,King BP,et al.Contribution of ag-e,body size,andCYP2C9 genotype to anticoagulant response to warfarin[J].Clin Pharmacol Ther,2004,75(3):204-212.
[12] Yin T,Miyata T.Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives[J].Thromb Res,2007,120(1):1-10.
[13] 杨 剑,缪丽燕,黄晨蓉,等.细胞色素氧化酶P450 2C9以及维生素K环氧化物还原酶复合体1基因多态性对华法林抗凝疗效的影响[J].中华心血管病杂志,2008,36(2):137-140.
Yang J,Miao LY,Huang CR,et al.Association between CYP2C9 and VKORC1genetic polymorphism and warfarin dose requirements[J]. Chin J Cardiol,2008,36(2):137-140.
[14] Bodin L,Verstuyft C,Tregouet DA,et al.Cyto-chrome P450 2C9(CYP2C9)and vitamin K epoxide reductase(VKORC1)genotype as determinants of acenocoumarolsensitivity[J].Blood,2005,106(1):135-140.
[15] Wadelius M,Chen LY,Downes K,et al.Common VKORC1 and GGCX polymorphisms associated with warfarin dose[J].Pharmacogenomics J,2005,5(4):262-270.
[16] 都丽萍.中国汉族人CYP2C9&VKORC1基因多态性及其与华法林个体化治疗的相关性研究[D].北京:北京协和医学院,2009.
Du LP.The association of CYP2C9 and VKORC1 polymorphisms and individualized warfarin therapy in population of han nationality in China[D].Beijing:Peking Union Medical College,2009.
[17] Kohnke H,Sorlin K,Granath G,et al.Warfarin dose related to apolipoprotein E(APOE)genotype[J].Eur J Clin Pharmacol,2005,61(5/6):381-388.
[18] Sconce EA,Daly AK,Khan TI,et al.APOE genotype makes a small contribution to warfarin dose requirements[J].Pharmacogenet Genomics,2006,16(8):609-611.
[19] Wadelius M,Sorlin K,Wallerman O,et al.Warfarin sensitivity related to CYP2C9,CYP3A5,ABCB1(MDR1)and other factors[J].Pharmacogenomics J,2004,4(1):40-48.
[20] Shikata E,Ieiri I,Ishiguro S,et al.Association 0f pharmacokinetic(CYP2C9)and pharmacodynamic(factors Ⅱ,Ⅶ,Ⅸ,and Ⅹ protein S and C and gamma-glutamyl carboxylase)gene variants with warfarin sensitivity[J].Blood,2004,103(7):2630-2635.
[21] Chen LY,Eriksson N,Gwillian R,et al.Gamma-glutamyl carboxylase(GGCX)microsatellite and warfarin dosing[J].Blood,2005,106(10):3673-3674.
[22] Loebstein R,Vecsler M,Kurnik D,et al.Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect ofcytochrome P450 2C9[J].Clin Pharamacol Ther,2005,77(5):365-372.
[23] Vecsler M,Loebstein R,Almog S,et al.Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin[J].Thromb Haemost,2006,95(2):205-211.